NCT02426281View on ClinicalTrials.gov

Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

June 4, 2015

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

nab-paclitaxel

nab- paclitaxel 125mg/m2 D1, 8 15 every 4 weeks.

DRUG

gemcitabine

gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.

Trial Locations (8)

Unknown

Dong-A University Hospital, Busan

Gyeongsang National University Hospital, Gyeongsang

CHA Bundang Medical Center, Seongnam-si

Asan Medical Center, Seoul

Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul

Seoul National University Hospital, Seoul

Severance Hospital, Yonsei Cancer Center, Seoul

06351

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02426281 - Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Biotech Hunter | Biotech Hunter